[Treatment of atrial fibrillation: behavioral, pharmacologic and catheter-based perspectives].
Atrial fibrillation (AF) is the most common heart rhythm disorder, with increasing prevalence in the aging population. The clinical presentation and evolution of AF can be highly variable. Therefore, treatment of AF can be challenging in some patients. This review summarizes recent developments in both prevention of thromboembolic events and rate/rhythm control highlighting the possibilities of behavioral, pharmacological, and catheter-based perspectives.
Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Düsseldorf. Christian.Meyer@med.uni-duesseldorf.de
Christian
C
Meyer
T
T
Rassaf
P
P
Schüller
M
M
Martinek
M
M
Kelm
H
H
Pürerfellner
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D017115:Catheter Ablation; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004554:Electric Countershock; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D004071:Digitalis Glycosides; D006493:Heparin